Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solutions, announce a strategic partnership. The companies will create a joint biomarker discovery workflow, leveraging Lexogen’s new single-cell RNA sequencing platform LUTHOR™ and Scailyte’s AI-driven analytics platform ScaiVision™.
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Michael Brenner MD, Elizabeth Fay Brigham Professor of Medicine at Harvard Medical School, has joined Scailyte as an advisor to the Board of Directors.
Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection May 21 2021 ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG. Recent News